Cybersecurity

Blood biomarker offers window into Alzheimer's drug response

30 sec read5 views0 listens

Researchers have identified changes in a blood-based biomarker, phosphorylated tau 217 (p-tau217), as a potential indicator of patient response to lecanemab, a treatment for early Alzheimer’s disease. This development is significant for cybersecurity because it could reduce the reliance on costly and complex brain scans to monitor treatment effectiveness, potentially expanding access to these therapies. Future studies should focus on validating these findings and determining how to best interpret p-tau217 levels in clinical practice.

Read the full article at Digital Journal

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

CybersecuritySep 926 sec read

Freezer-free RNA vaccine breakthrough could transform the global fight against emerging diseases

Immunoscript Life Science has secured $8.9 million from CEPI to advance clinical testing of a new RNA vaccine platform that can be stored at regular refrigeration temperatures, addressing the cold chain challenge in vaccine distribution. This breakth...

Ali Nemati

CybersecurityJul 2226 sec read

I Built a Splunk SIEM Lab and Got 100% Detection on Every Real Attack I Threw At It

A cybersecurity expert built a Splunk SIEM lab that achieved 100% detection accuracy across various real attack simulations. This hands-on approach validates the effectiveness of custom detection rules and threat hunting capabilities in Splunk, cruci...

Ali Nemati

Biotech & PharmaJun 1232 sec read

STAT+: Pharmalittle: We're reading about a discontinued cancer drug, a Novo security breach, and more

The nonprofit Blood Cancer United has acquired the remaining supplies and investigational rights for the discontinued drug Luvelta to continue providing it to children with rare blood cancers. This unusual move highlights a critical shift in the phar...

Ali Nemati